Further re. financial update and funding plans

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

Further re. financial update and funding plans

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides a further update to its financial position.

Further to the announcement of 7 November 2025, the Senior Leadership Team continues to clarify the immediate funding needs of the business and the larger capital sum needed to restore revenue growth. The Company has secured an emergency overdraft of $500K from MidCap, its existing lender, which has allowed Tissue Regenix to make November payroll and remain solvent. The Company remains in dialogue with its major shareholders with respect to its short- and medium-term funding requirement and expects to provide a further update and post a circular to shareholders later this week.

The Company still expects to raise funds by way of a convertible loan note and will provide an update in due course. Any fundraise will be subject to shareholder approval.

For more information, please contact:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.